A. . Blauvelt, “Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials”, J of Skin, vol. 6, no. 4, p. s41, Jul. 2022.